These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2550424)

  • 21. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
    Lijnen HR; Wnendt S; Schneider J; Janocha E; Van Hoef B; Collen D; Steffens GJ
    Eur J Biochem; 1995 Nov; 234(1):350-7. PubMed ID: 8529664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
    Grimsley PG; Normyle JF; Brandt RA; Joulianos G; Chesterman CN; Hogg PJ; Owensby DA
    Thromb Res; 1995 Aug; 79(4):353-61. PubMed ID: 7482438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The interaction of recombinant tissue type plasminogen activator and recombinant plasminogen activator (r-PA/BM 06.022) with human endothelial cells.
    Mulder M; Kohnert U; Fischer S; van Hinsbergh VW; Verheijen JH
    Blood Coagul Fibrinolysis; 1997 Mar; 8(2):124-33. PubMed ID: 9518044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow.
    Whyte CS; Swieringa F; Mastenbroek TG; Lionikiene AS; Lancé MD; van der Meijden PE; Heemskerk JW; Mutch NJ
    Blood; 2015 Apr; 125(16):2568-78. PubMed ID: 25712989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells.
    Miles LA; Plow EF
    Thromb Haemost; 1987 Oct; 58(3):936-42. PubMed ID: 2829380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen.
    Hajjar KA
    J Biol Chem; 1991 Nov; 266(32):21962-70. PubMed ID: 1657983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation.
    Martínez C; Rivera J; Loyau S; Corral J; González-Conejero R; Lozano ML; Vicente V; Anglés-Cano E
    Thromb Haemost; 2001 Apr; 85(4):686-93. PubMed ID: 11341506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation.
    Shattil SJ; Hoxie JA; Cunningham M; Brass LF
    J Biol Chem; 1985 Sep; 260(20):11107-14. PubMed ID: 2411729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
    Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
    J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp130 and Ser139 of urokinase-type plasminogen activator.
    Lijnen HR; Piérard L; Reff ME; Gheysen D
    Thromb Res; 1988 Dec; 52(5):431-41. PubMed ID: 3146822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis.
    Stringer HA; Pannekoek H
    J Biol Chem; 1995 May; 270(19):11205-8. PubMed ID: 7744752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The inactivation of single-chain urokinase-type plasminogen activator by thrombin on cultured human endothelial cells.
    Braat EA; Collen A; Jie AF; Grimbergen JM; Rijken DC
    Biochim Biophys Acta; 2000 Sep; 1497(3):351-8. PubMed ID: 10996659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis.
    Fleury V; Lijnen HR; Anglés-Cano E
    J Biol Chem; 1993 Sep; 268(25):18554-9. PubMed ID: 8103046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variants of human tissue-type plasminogen activator. Fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains.
    Larsen GR; Henson K; Blue Y
    J Biol Chem; 1988 Jan; 263(2):1023-9. PubMed ID: 3121618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E.
    Stewart RJ; Fredenburgh JC; Weitz JI
    J Biol Chem; 1998 Jul; 273(29):18292-9. PubMed ID: 9660794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies on the release of a plasminogen activator inhibitor by human platelets.
    Kruithof EK; Tran-Thang C; Bachmann F
    Thromb Haemost; 1986 Apr; 55(2):201-5. PubMed ID: 2940723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the effects of fibrin binding on the biochemical properties of single-chain tissue-type plasminogen activator (t-PA) and single-chain chimeric plasminogen activator (t-PA/scu-PA).
    Fischer BE
    Blood Coagul Fibrinolysis; 1992 Feb; 3(1):39-46. PubMed ID: 1320415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
    Sitter T; Toet K; Quax P; Kooistra T
    Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.